Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total value of $692,080.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,472,066.41. The trade was a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $88.78, for a total value of $710,240.00.

Vaxcyte Trading Down 1.7 %

NASDAQ PCVX traded down $1.53 during mid-day trading on Wednesday, hitting $86.64. The company's stock had a trading volume of 1,666,646 shares, compared to its average volume of 1,344,304. The firm has a market capitalization of $10.80 billion, a price-to-earnings ratio of -18.83 and a beta of 0.98. The company's 50 day simple moving average is $87.49 and its 200 day simple moving average is $93.93. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business posted ($0.91) earnings per share. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Institutional Trading of Vaxcyte

Several institutional investors and hedge funds have recently modified their holdings of the stock. Riverview Trust Co bought a new position in shares of Vaxcyte in the third quarter valued at approximately $27,000. Blue Trust Inc. grew its stake in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares during the period. Meeder Asset Management Inc. raised its stake in shares of Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after purchasing an additional 635 shares during the period. Nomura Asset Management Co. Ltd. purchased a new position in shares of Vaxcyte in the 3rd quarter worth about $92,000. Finally, Signaturefd LLC grew its position in Vaxcyte by 51.9% during the third quarter. Signaturefd LLC now owns 1,048 shares of the company's stock valued at $120,000 after buying an additional 358 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on PCVX. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 target price on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and an average price target of $145.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.